Stock Analysts’ updated eps estimates for Thursday, August 10th:
Airgain (NASDAQ:AIRG) had its buy rating reaffirmed by analysts at Cowen and Company. The firm currently has a $19.00 price target on the stock.
AMAG Pharmaceuticals (NASDAQ:AMAG) had its hold rating reiterated by analysts at Cowen and Company.
Amtech Systems (NASDAQ:ASYS) had its buy rating reiterated by analysts at Benchmark Co.. Benchmark Co. currently has a $12.00 target price on the stock. The analysts wrote, “We have raised our target price from $10 to $12 which corresponds to a forward multiple of 16 after adjustment for net cash/share. Raising Target Price Rating: Buy Current Price $9.64 Price Target $12.00 52-Wk Range $3.99 – $9.68 Market Cap $127 Shares Outstanding 13.1 Average Volume (30 day) 73,692 Float 10.8 Net Cash/Share $2.20 Sector Weight Market Weight Mark Miller 925-648-2692 [email protected]/* */ FY Sep Q1 Q2 Q3 Q4 Total P/E EPS 2016A ($0.31)A ($0.11)A ($0.09)A ($0.02)A ($0.53)A 2017E ($0.00)A ($0.11)A $0.25A $0.17E $0.31E 31.1 2018E $0.26E $0.17E $0.12E $0.05E $0.60E 16.1 Revenue (m) 2016A $22.1A $22.5A $33.3A $42.4A $120.3A 2017E $29.1A $32.9A $47.8A $47.5E $157.3E 2018E $53.0E $47.5E $44.0E $39.0E $183.5E Amtech Systems (ASYS) August 10, 2017 Page 2 Analysis and Investment Recommendation Amtech’s reported net GAAP income of $0.25 per diluted share was 31 cents upside to investor expectations, while sales of $47.8 million exceeded investor expectations by $7.4 million. Strength was noted among all three segments: solar, semi, and polishing. June quarter gross margins of 32.5% were up 700 bps sequentially and 360 bps Y/Y.””
BioScrip (NASDAQ:BIOS) had its buy rating reissued by analysts at Jefferies Group LLC. The firm currently has a $4.00 price target on the stock, up from their previous price target of $3.00.
Bellicum Pharmaceuticals (NASDAQ:BLCM) had its buy rating reaffirmed by analysts at Jefferies Group LLC. The firm currently has a $16.00 target price on the stock, down from their previous target price of $18.00.
BioSpecifics Technologies Corp (NASDAQ:BSTC) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $72.00 target price on the stock. The analysts wrote, “We have adjusted our revenue projection for BSTC accordingly, and our current 2017 revenue projection is $28.0M vs. the prior $29.6M, suggesting 7% YoY growth, while our 2018 revenue estimate is now $29.4M vs. the prior $32M.””
Capital & Counties Properties PLC (LON:CAPC) had its buy rating reiterated by analysts at Numis Securities Ltd. They currently have a GBX 75 ($0.98) price target on the stock.
Capital & Counties Properties PLC (LON:CAPC) had its hold rating reissued by analysts at Peel Hunt. The firm currently has a GBX 61 ($0.79) price target on the stock.
Credit Suisse Group (NYSE:CS) had its buy rating reiterated by analysts at Citigroup Inc..
Barclays PLC began coverage on shares of Delta Air Lines (NYSE:DAL). Barclays PLC issued an overweight rating on the stock.
Walt Disney Company (The) (NYSE:DIS) had its hold rating reaffirmed by analysts at Cowen and Company. Cowen and Company currently has a $95.00 target price on the stock.
Drillisch AG (ETR:DRI) had its buy rating reiterated by analysts at DZ Bank AG.
DXC Technology Company. (NYSE:DXC) had its hold rating reiterated by analysts at Cowen and Company. The firm currently has a $77.00 price target on the stock.
Energy Focus (NASDAQ:EFOI) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $6.00 target price on the stock. The analysts wrote, “We believe growth in revenues for the company over the near term is largely dependent on execution in the Commercial segment. The company generated a gross profit of $1.5M for the quarter. We believe gross margins should return to low- to mid-30% levels once the company begins selling its newer low-cost inventory and should trend toward ~35% during 2018. Net loss for 2Q17 was $3.1M, or ($0.26) per diluted share, compared to net loss of $3.9M, or ($0.34) per diluted share during 2Q16.””
Endo International PLC (NASDAQ:ENDP) had its neutral rating reissued by analysts at Citigroup Inc.. Citigroup Inc. currently has a $11.00 target price on the stock, down from their previous target price of $14.00.
Endo International PLC (NASDAQ:ENDP) had its hold rating reissued by analysts at Cowen and Company. Cowen and Company currently has a $16.00 price target on the stock.
FedEx Corporation (NYSE:FDX) had its buy rating reissued by analysts at Cowen and Company. They currently have a $240.00 target price on the stock.
Flowserve Corporation (NYSE:FLS) had its buy rating reaffirmed by analysts at Cowen and Company. Cowen and Company currently has a $50.00 price target on the stock.
Forward Air Corporation (NASDAQ:FWRD) had its hold rating reaffirmed by analysts at Cowen and Company. Cowen and Company currently has a $51.00 price target on the stock.
Green Dot Corporation (NYSE:GDOT) had its hold rating reaffirmed by analysts at Cowen and Company.
Ionis Pharmaceuticals (NASDAQ:IONS) had its underperform rating reaffirmed by analysts at Jefferies Group LLC. They currently have a $18.00 target price on the stock, up from their previous target price of $17.00.
Inter Parfums (NASDAQ:IPAR) had its buy rating reissued by analysts at Citigroup Inc.. The firm currently has a $45.00 price target on the stock, up from their previous price target of $42.00.
Janus Capital Group (NYSE:JHG) had its neutral rating reiterated by analysts at Citigroup Inc.. Citigroup Inc. currently has a $37.00 price target on the stock, up from their previous price target of $34.50.
Klondex Mines (NASDAQ:KLDX) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $6.25 target price on the stock. The analysts wrote, “We highlight that our updated model now includes a DCF of operations at Hollister. That said, we project gold equivalent production to total 228,200 ounces in 2017, an increase over our prior forecast of 219,400 ounces and toward the higher end of the company’s revised guidance. We attribute this to slightly higher-than-expected production from the Nevada operations in 2Q17. We also raised our projected 2017 consolidated cash costs per GEO slightly to $679 to reflect higher-than- expected costs at True North. Overall, these changes mainly offset each other, resulting in a minimal impact to our overall valuation. Record 2Q17 throughput from the Nevada operations helped to boost overall production. We highlight that the Midas mill processed 92,232 tonnes or ore from both Fire Creek and Midas in 2Q17 for a 7% YoY increase. Record throughput, along with higher-than-expected grades at Midas and Fire Creek, contributed to a 43% increase in gold equivalent ounces produced over 2Q16. We believe that the Nevada operations can continue to outperform, given that the Midas mill is expected to process Hollister ore in 2H17.””
Karyopharm Therapeutics (NASDAQ:KPTI) had its buy rating reaffirmed by analysts at Jefferies Group LLC. Jefferies Group LLC currently has a $19.00 price target on the stock, up from their previous price target of $16.00.
LendingClub Corporation (NYSE:LC) had its neutral rating reiterated by analysts at Citigroup Inc.. Citigroup Inc. currently has a $6.50 price target on the stock, up from their previous price target of $6.00.
Lumentum Holdings (NASDAQ:LITE) had its overweight rating reiterated by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $68.00 target price on the stock.
Life Storage (NYSE:LSI) had its buy rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $85.00 price target on the stock, down from their previous price target of $98.00.
The Medicines (NASDAQ:MDCO) had its buy rating reaffirmed by analysts at Cowen and Company. The firm currently has a $54.00 target price on the stock.
Pagegroup PLC (LON:MPI) had its buy rating reiterated by analysts at Liberum Capital. Liberum Capital currently has a GBX 455 ($5.93) price target on the stock.
Micron Technology (NASDAQ:MU) had its buy rating reissued by analysts at Cowen and Company.
Myriad Genetics (NASDAQ:MYGN) had its hold rating reiterated by analysts at Jefferies Group LLC. The firm currently has a $23.00 target price on the stock, up from their previous target price of $21.00.
Plains All American Pipeline, L.P. (NYSE:PAA) had its buy rating reissued by analysts at Citigroup Inc.. They currently have a $28.00 target price on the stock, down from their previous target price of $33.50.
Plains Group Holdings, L.P. (NYSE:PAGP) had its buy rating reaffirmed by analysts at Citigroup Inc.. Citigroup Inc. currently has a $28.00 target price on the stock, down from their previous target price of $33.50.
The Priceline Group (NASDAQ:PCLN) had its buy rating reiterated by analysts at Jefferies Group LLC. They currently have a $2,300.00 price target on the stock, up from their previous price target of $2,250.00.
Public Service Enterprise Group (NYSE:PEG) had its neutral rating reissued by analysts at Citigroup Inc.. The firm currently has a $49.00 target price on the stock, up from their previous target price of $44.00.
PRA Health Sciences (NASDAQ:PRAH) had its buy rating reissued by analysts at Citigroup Inc.. Citigroup Inc. currently has a $93.00 target price on the stock, up from their previous target price of $90.00.
Resonant (NASDAQ:RESN) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $8.00 target price on the stock.
Synergy Pharmaceuticals (NASDAQ:SGYP) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $15.00 target price on the stock. The analysts wrote, “We note that the launch of Trulance appears to be progressing on multiple fronts, with the company having reached 66% of its targeted prescriber base and over 90% of the high-volume prescribers (deciles 8-10). According to QuintilesIMS data, as of mid-2017 over 12,600 Trulance prescriptions had been filled and total monthly prescription volume has increased on average over 182% month-over-month during that period. Over 32% of all high prescribers had written a Trulance prescription since the drug was launched earlier this year, with an average increase for all prescribers of approximately 140% month-over-month. Trulance achieved 6.8% new-to-brand prescription (NBRx) total market share and 12% NBRx market share among gastroenterologists. Importantly, about 55% of new Trulance prescriptions filled since launch were coming from new patients not previously on a branded prescription treatment and 45% were patients who converted from other branded prescription treatments.””
TE Connectivity (NYSE:TEL) had its buy rating reissued by analysts at Cowen and Company. Cowen and Company currently has a $95.00 price target on the stock.
Tenet Healthcare Corporation (NYSE:THC) had its neutral rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $16.00 price target on the stock, down from their previous price target of $20.00.
Triton International Limited (NASDAQ:TRTN) had its buy rating reissued by analysts at Cowen and Company. Cowen and Company currently has a $44.00 price target on the stock.
UBS Group AG (VTX:UBSG) had its buy rating reissued by analysts at Citigroup Inc..
Virtu Financial (NASDAQ:VIRT) had its sell rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $14.00 target price on the stock, down from their previous target price of $16.00.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) had its buy rating reaffirmed by analysts at Stifel Nicolaus. The firm currently has a $35.00 price target on the stock.
